Published in FEBS Lett on September 25, 2002
FGFR3 dimer stabilization due to a single amino acid pathogenic mutation. J Mol Biol (2005) 1.59
Defective lysosomal targeting of activated fibroblast growth factor receptor 3 in achondroplasia. Proc Natl Acad Sci U S A (2003) 1.44
Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias. Hum Mutat (2011) 1.35
Ubiquitination of fibroblast growth factor receptor 1 is required for its intracellular sorting but not for its endocytosis. Mol Biol Cell (2008) 1.19
Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner. Oncogene (2009) 1.17
Constitutively activated FGFR3 mutants signal through PLCgamma-dependent and -independent pathways for hematopoietic transformation. Blood (2005) 1.13
Sprouty 2 disturbs FGFR3 degradation in thanatophoric dysplasia type II: a severe form of human achondroplasia. Cell Signal (2008) 1.08
Receptor tyrosine kinase transmembrane domains: Function, dimer structure and dimerization energetics. Cell Adh Migr (2010) 1.06
Tyrosine residues direct the ubiquitination and degradation of the NY-1 hantavirus G1 cytoplasmic tail. J Virol (2003) 1.02
Neutron diffraction studies of fluid bilayers with transmembrane proteins: structural consequences of the achondroplasia mutation. Biophys J (2006) 1.00
Physical basis behind achondroplasia, the most common form of human dwarfism. J Biol Chem (2010) 0.99
The control of transmembrane helix transverse position in membranes by hydrophilic residues. J Mol Biol (2007) 0.98
The A391E mutation enhances FGFR3 activation in the absence of ligand. Biochim Biophys Acta (2011) 0.92
The physical basis of FGFR3 response to fgf1 and fgf2. Biochemistry (2011) 0.91
Fibroblast growth factor receptor 3 (FGFR3) is a strong heat shock protein 90 (Hsp90) client: implications for therapeutic manipulation. J Biol Chem (2011) 0.90
Ligand activation leads to regulated intramembrane proteolysis of fibroblast growth factor receptor 3. Mol Biol Cell (2011) 0.82
Endocytosis of Fgf8 is a double-stage process and regulates spreading and signaling. PLoS One (2014) 0.78
Effects of diadenosine tetraphosphate on FGF9-induced chloride flux changes in achondroplastic chondrocytes. Purinergic Signal (2011) 0.76
Effect of the G375C and G346E achondroplasia mutations on FGFR3 activation. PLoS One (2012) 0.76
The impact of polyphenols on chondrocyte growth and survival: a preliminary report. Food Nutr Res (2015) 0.75
Molecular therapeutic strategies for FGFR3 gene-related skeletal dysplasia. J Mol Med (Berl) (2017) 0.75
Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol Cell (2000) 5.72
Programmable and autonomous computing machine made of biomolecules. Nature (2001) 3.51
A novel functional human eukaryotic translation initiation factor 4G. Mol Cell Biol (1998) 3.49
Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells. Mol Cell Biol (1992) 3.41
Developmental localization of the splicing alternatives of fibroblast growth factor receptor-2 (FGFR2). Dev Biol (1993) 2.96
Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis. Cell (1994) 2.23
Developmental expression of two murine fibroblast growth factor receptors, flg and bek. Development (1991) 2.16
Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc Natl Acad Sci U S A (1996) 2.12
Identification of the acidic compartment of Plasmodium falciparum-infected human erythrocytes as the target of the antimalarial drug chloroquine. EMBO J (1984) 2.11
Complexity of FGF receptors: genetic basis for structural diversity and functional specificity. FASEB J (1992) 2.00
Palmar hyperhidrosis and its surgical treatment: a report of 100 cases. Ann Surg (1977) 1.97
Fatal complications of central venous catheters. Br Med J (1971) 1.92
ErbB-3 and ErbB-4 function as the respective low and high affinity receptors of all Neu differentiation factor/heregulin isoforms. J Biol Chem (1994) 1.88
Cellular sensitivity to collagen in thromboangiitis obliterans. N Engl J Med (1983) 1.79
A mouse model for achondroplasia produced by targeting fibroblast growth factor receptor 3. Proc Natl Acad Sci U S A (1999) 1.75
Stage-dependent effects of chloroquine on Plasmodium falciparum in vitro. J Protozool (1983) 1.70
Anti-Escherichia coli adhesin activity of cranberry and blueberry juices. N Engl J Med (1991) 1.64
Susceptibility of human malaria parasites to chloroquine is pH dependent. Proc Natl Acad Sci U S A (1985) 1.62
Gly369Cys mutation in mouse FGFR3 causes achondroplasia by affecting both chondrogenesis and osteogenesis. J Clin Invest (1999) 1.62
Early reoperation for perirectal abscess: a preventable complication. Dis Colon Rectum (2001) 1.49
Effects of chloroquine on the feeding mechanism of the intraerythrocytic human malarial parasite Plasmodium falciparum. J Protozool (1984) 1.46
Inhibitory activity of cranberry juice on adherence of type 1 and type P fimbriated Escherichia coli to eucaryotic cells. Antimicrob Agents Chemother (1989) 1.45
The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation. Mol Cell Biol (2000) 1.38
The human homologue of the yeast Prt1 protein is an integral part of the eukaryotic initiation factor 3 complex and interacts with p170. J Biol Chem (1997) 1.29
Receptors of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in fetal and adult human kidney: localization and [125I]VEGF binding sites. J Am Soc Nephrol (1998) 1.22
Type I procollagen C-proteinase from mouse fibroblasts. Purification and demonstration of a 55-kDa enhancer glycoprotein. Eur J Biochem (1989) 1.21
Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor. Hum Gene Ther (1998) 1.19
Differential expression of the two VEGF receptors flt and KDR in placenta and vascular endothelial cells. J Cell Biochem (1994) 1.18
Differential structural requirements of heparin and heparan sulfate proteoglycans that promote binding of basic fibroblast growth factor to its receptor. J Biol Chem (1994) 1.15
Differential binding characteristics and cellular inhibition by soluble VEGF receptors 1 and 2. Exp Cell Res (1998) 1.12
Distribution and symmetry of arteriosclerotic lesions of the lower extremities: an arteriographic study of 200 limbs. Cardiovasc Intervent Radiol (1985) 1.12
A unified pathway for the degradation of ornithine decarboxylase in reticulocyte lysate requires interaction with the polyamine-induced protein, ornithine decarboxylase antizyme. Eur J Biochem (1994) 1.11
Heparin-dependent binding and autophosphorylation of epidermal growth factor (EGF) receptor by heparin-binding EGF-like growth factor but not by EGF. Proc Natl Acad Sci U S A (1994) 1.09
Hydromediastinum. JAMA (1970) 1.07
Skeletal dysplasia and defective chondrocyte differentiation by targeted overexpression of fibroblast growth factor 9 in transgenic mice. J Bone Miner Res (1999) 1.06
Vascular lesions associated with impotence in diabetic and nondiabetic arterial occlusive disease. Diabetes (1978) 1.06
Fibroblast growth factor receptor-3 as a marker for precartilaginous stem cells. Clin Orthop Relat Res (1999) 1.04
Properly oriented heparin-decasaccharide-induced dimers are the biologically active form of basic fibroblast growth factor. Biochemistry (1997) 1.03
Restrained chondrocyte proliferation and maturation with abnormal growth plate vascularization and ossification in human FGFR-3(G380R) transgenic mice. Hum Mol Genet (2000) 1.03
Induction of Mdm2 and enhancement of cell survival by bFGF. Oncogene (1997) 1.03
T2 mapping and dGEMRIC after autologous chondrocyte implantation with a fibrin-based scaffold in the knee: preliminary results. Eur J Radiol (2009) 1.01
Suppression of autocrine and paracrine functions of basic fibroblast growth factor by stable expression of perlecan antisense cDNA. Mol Cell Biol (1997) 1.01
Esophageal ulceration and oral potassium chloride ingestion. Chest (1974) 1.01
Angiographic diagnosis and differential diagnosis of islet-cell tumors. Am J Roentgenol Radium Ther Nucl Med (1973) 1.01
Complications of saphenous vein harvesting following coronary artery bypass surgery. J Cardiovasc Surg (Torino) (1990) 1.01
Expression of fibrinolytic genes in atherosclerotic abdominal aortic aneurysm wall. A possible mechanism for aneurysm expansion. J Clin Invest (1995) 1.00
Heparan sulfate primed on beta-D-xylosides restores binding of basic fibroblast growth factor. J Cell Biochem (1995) 0.99
Effects of mitochondrial protein synthesis inhibitors on the incorporation of isoleucine into Plasmodium falciparum in vitro. J Protozool (1984) 0.98
Arteriovenous vein graft for chronic hemodialysis: a preliminary report. Surgery (1970) 0.97
A novel form of FGF receptor-3 using an alternative exon in the immunoglobulin domain III. FEBS Lett (1993) 0.97
C-terminal post-translational proteolysis of plant lectins and their recombinant forms expressed in Escherichia coli. Characterization of "ragged ends" by mass spectrometry. J Biol Chem (1995) 0.95
Effects of modulation of basic fibroblast growth factor on tumor growth in vivo. J Natl Cancer Inst (1993) 0.95
Identification of fibroblast growth factor 9 (FGF9) as a high affinity, heparin dependent ligand for FGF receptors 3 and 2 but not for FGF receptors 1 and 4. Growth Factors (1995) 0.95
The use of arteriovenous autograft and allograft fistulas for chronic hemodialysis. Surg Gynecol Obstet (1973) 0.95
Iliopsoas injury in soccer players. Br J Sports Med (1985) 0.94
Abnormal FGFR 3 expression in cartilage of thanatophoric dysplasia fetuses. Hum Mol Genet (1997) 0.94
The effect of ischemia of the dog's colon on transmural migration of bacteria and endotoxin. J Surg Res (1983) 0.93
A point scoring system for the clinical diagnosis of Buerger's disease. Eur J Vasc Endovasc Surg (1996) 0.93
Porphyrin analogues as novel antagonists of fibroblast growth factor and vascular endothelial growth factor receptor binding that inhibit endothelial cell proliferation, tumor progression, and metastasis. Cancer Res (2000) 0.93
Flg-2, a new member of the family of fibroblast growth factor receptors. Oncogene (1991) 0.92
Results of chondrocyte implantation with a fibrin-hyaluronan matrix: a preliminary study. Clin Orthop Relat Res (2008) 0.92
Chloroquine inhibits the degradation of endocytic vesicles in human malaria parasites. Cell Biol Int Rep (1983) 0.92
Autoimmune mechanisms in thromboangiitis obliterans (Buerger's disease): the role of tobacco antigen and the major histocompatibility complex. Surgery (1992) 0.92
Multiple structural elements determine ligand binding of fibroblast growth factor receptors. Evidence that both Ig domain 2 and 3 define receptor specificity. J Biol Chem (1993) 0.92
Upper dorsal sympathectomy for palmar hyperhidrosis. Isr J Med Sci (1983) 0.92
Close similarity among streptavidin-like, biotin-binding proteins from Streptomyces. Biochim Biophys Acta (1995) 0.91
Budd-Chiari syndrome. Study of angiographic findings and remarks on etiology. Am J Roentgenol Radium Ther Nucl Med (1972) 0.91
Controlled trial of propranolol in intermittent claudication. Clin Pharmacol Ther (1975) 0.91
Diminished heparin binding of a basic fibroblast growth factor mutant is associated with reduced receptor binding, mitogenesis, plasminogen activator induction, and in vitro angiogenesis. Biochemistry (1994) 0.91
Molecular modeling based mutagenesis defines ligand binding and specificity determining regions of fibroblast growth factor receptors. Biochemistry (1995) 0.91
External iliac artery blood flow in patients with arteriosclerosis obliterans. Am J Roentgenol Radium Ther Nucl Med (1975) 0.90
Cardiovascular changes after bilateral upper dorsal sympathectomy. Short- and long-term effects. Ann Surg (1986) 0.90
Evidence for a protein that enhances the activity of type I procollagen C-proteinase. Coll Relat Res (1986) 0.90
Contribution of the circle of Willis to the subclavian steal syndrome. Circulation (1969) 0.89
FGF upregulates osteopontin in epiphyseal growth plate chondrocytes: implications for endochondral ossification. Matrix Biol (2005) 0.88
Letter: Buerger's disease--the need for diagnostic criteria. Surgery (1974) 0.88
Percutaneous transluminal angioplasty. A suggested method for analysis of clinical, arteriographic, and hemodynamic factors affecting the results of treatment. J Vasc Surg (1986) 0.87
Femoral neuropathy complicating systemic streptokinase treatment for ergotism. Angiology (1979) 0.87
Multiple tumor emboli after lung resection. J Cardiovasc Surg (Torino) (1989) 0.86
Axillary artery injury in erect dislocation of the shoulder. J Trauma (1981) 0.86
Partial purification and characterization of a procollagen C-proteinase from the culture medium of mouse fibroblasts. Coll Relat Res (1986) 0.86
The association of atherosclerosis and Buerger's disease: a clinical and radiological study. J Cardiovasc Surg (Torino) (1970) 0.86
Detection and quantification of complexed and free soluble human vascular endothelial growth factor receptor-1 (sVEGFR-1) by ELISA. J Immunol Methods (1999) 0.85
Pulmonary functional abnormalities after upper dorsal sympathectomy. A comparison between the supraclavicular and transaxillary approaches. Chest (1980) 0.85
Basic fibroblast growth factor: a potential inhibitor of glutamine synthetase expression in injured neural tissue. J Neurochem (2001) 0.85
Reversal of basic fibroblast growth factor-mediated autocrine cell transformation by aromatic anionic compounds. Cancer Res (1992) 0.85
The manipulated mesenchymal stem cells in regenerated skeletal tissues. Cell Transplant (1998) 0.85
Upper dorsal sympathectomy for palmar primary hyperhidrosis by the supraclavicular approach. World J Surg (1977) 0.85
Effect of dehydration and cardiac tamponade on superior mesenteric artery flow: role of vasoactive substances. Surgery (1976) 0.84
Pulmonary functional abnormalities after upper dorsal sympathectomy. Am Rev Respir Dis (1977) 0.84
Patterns of expression of fibrinolytic genes and matrix metalloproteinase-9 in dissecting aortic aneurysms. Am J Pathol (1998) 0.83
[The controversy over a method of intravenous hyperalimentation in cirrhotic patients]. Harefuah (1977) 0.83
Characteristics of cartilage biopsies used for autologous chondrocytes transplantation. Cell Transplant (2001) 0.83
Aortic false aneurysm following blunt trauma of the abdomen. J Trauma (1983) 0.82
[Surgery for thoraco-abdominal aortic aneurysm]. Harefuah (1991) 0.82
The role of infection in post-mastectomy lymphedema. Surg Annu (1982) 0.82
Engineering of fibroblast growth factor: alteration of receptor binding specificity. Biochemistry (1995) 0.82